AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8192646 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical ratings
Number of subjects: 0
Study 8192646 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral performance measures
Number of subjects: 0
Study 8192646 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite index
Number of subjects: 0
Study 3555692 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure and proximal gastric vagotomy
Number of subjects: 50
Study 3555692 — intervention group
Group type: COMPARATOR
Intervention: Simple closure
Number of subjects: 50
Study 30217726 — intervention group
Group type: EXPERIMENTAL
Intervention: General endotracheal anesthesia (GEA)
Number of subjects: 200
Study 30217726 — intervention group
Group type: COMPARATOR
Intervention: Monitored anesthesia care (MAC)
Number of subjects: 200
Study 30217726 — intervention group
Group type: EXPERIMENTAL
Intervention: General endotracheal anesthesia (GEA) and Monitored anesthesia care (MAC)
Number of subjects: 200
Study 28053275 — intervention group
Group type: EXPERIMENTAL
Intervention: BVAS (Baseline Vasculitis Activity Score)
Number of subjects: 417
Study 28053275 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent development of malignancy
Number of subjects: 417
Study 28053275 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucous membrane or eye involvement
Number of subjects: 417
Study 28053275 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline creatinine
Number of subjects: 417
Study 28053275 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP (C-reactive protein) increase (per 10 mg/l)
Number of subjects: 417
Study 28053275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous involvement
Number of subjects: 417
Study 28053275 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal involvement
Number of subjects: 417
Study 28053275 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline creatinine increase (per 100 µmol/l)
Number of subjects: 417
Study 26095242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 26095242 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d of vitamin D3
Number of subjects: 328
Study 26095242 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3
Number of subjects: 328
Study 26095242 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d of vitamin D3
Number of subjects: 328
Study 23219108 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein diet (25% of energy intake)
Number of subjects: 164
Study 23219108 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate diet (15% of energy intake)
Number of subjects: 164
Study 23219108 — intervention group
Group type: COMPARATOR
Intervention: Unsaturated fat diet (15% of energy intake)
Number of subjects: 164
Study 21854503 — intervention group
Group type: EXPERIMENTAL
Intervention: SBR759 (3.0 or 4.5 g/day)
Number of subjects: 203
Study 21854503 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride (2.4 or 4.8 g/day)
Number of subjects: 203
Study 21854503 — intervention group
Group type: EXPERIMENTAL
Intervention: SBR759
Number of subjects: 203
Study 17971091 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a (40KD) 180μg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Number of subjects: 0
Study 17971091 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a (40KD) plus ribavirin
Number of subjects: 0
Study 17971091 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with elevated ALT levels)
Number of subjects: 0
Study 16947384 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg by weight range)
Number of subjects: 0
Study 16947384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16947384 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 16947384 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept plus biologic agent
Number of subjects: 0
Study 16947384 — intervention group
Group type: EXPERIMENTAL
Intervention: Other subgroups (not receiving biologic agent)
Number of subjects: 0
Study 12969096 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital plus remifentanil (0.625 mg kg‐1 methohexital + 1 micro g kg‐1 remifentanil)
Number of subjects: 7
Study 12969096 — intervention group
Group type: COMPARATOR
Intervention: Methohexital alone (1.25 mg kg‐1)
Number of subjects: 7
Study 12969096 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital plus remifentanil
Number of subjects: 7
Study 12969096 — intervention group
Group type: COMPARATOR
Intervention: Methohexital alone
Number of subjects: 7
Study 11885170 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 3000
Study 11885170 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HA-coated implants
Number of subjects: 3000
Study 11885170 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants mobile at uncovering
Number of subjects: 3000
Study 11885170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone quality-4
Number of subjects: 3000
Study 11885170 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with facial bone thickness >= 1.8 mm
Number of subjects: 3000
Study 11885170 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants that failed to integrate
Number of subjects: 3000
Study 11885170 — intervention group
Group type: COMPARATOR
Intervention: HA-coated vs non-HA-coated implants
Number of subjects: 3000
Study 9383226 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate administration of G-CSF (day +1)
Number of subjects: 70
Study 9383226 — intervention group
Group type: COMPARATOR
Intervention: Delayed, patient-dependent G-CSF therapy (first day when ANC was below 0.5 x 10[9]/1)
Number of subjects: 70
Study 8463731 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prednisolone phosphate 1.0% administered 4 times daily to the right eye
Number of subjects: 13
Study 8463731 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to the left eye
Number of subjects: 13
Study 8463731 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prednisolone phosphate 1.0%
Number of subjects: 13
Study 3534869 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril once daily (100 mg)
Number of subjects: 9
Study 3534869 — intervention group
Group type: COMPARATOR
Intervention: Captopril twice daily (50 mg)
Number of subjects: 9
Study 30143950 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS® intervention (14-week parent-assisted training)
Number of subjects: 72
Study 30143950 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 72
Study 29708400 — intervention group
Group type: EXPERIMENTAL
Intervention: Video follow-up (VF)
Number of subjects: 0
Study 29708400 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinic follow-up (CF)
Number of subjects: 0
Study 27779951 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Vision Goggles (NVG) during flight simulation
Number of subjects: 4
Study 27779951 — intervention group
Group type: COMPARATOR
Intervention: Standard helmet only (Control) during flight simulation
Number of subjects: 4
Study 24814735 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR with SMR access
Number of subjects: 62
Study 24814735 — intervention group
Group type: COMPARATOR
Intervention: EMR without SMR access
Number of subjects: 62
Study 22132827 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin trihydrate-potassium clavulanate (Clavamox)
Number of subjects: 19
Study 22132827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20940176 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma levels of PFOS (ng/mL)
Number of subjects: 1010
Study 20940176 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma levels of PFOA (ng/mL)
Number of subjects: 1010
Study 20940176 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index measurements
Number of subjects: 1010
Study 20940176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex stratification
Number of subjects: 1010
Study 18723709 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg, max 10 mg over 5 min)
Number of subjects: 71
Study 18723709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 71
Study 15941955 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENT intervention (telephone-delivered intervention plus tailored materials)
Number of subjects: 1247
Study 15941955 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1247
Study 15941955 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENT intervention
Number of subjects: 1247
Study 12954462 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted standard deviation (SD) used in sample size calculation
Number of subjects: 0
Study 12954462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size calculation
Number of subjects: 0
Study 10561339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 11064
Study 10561339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11064
Study 8934257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical treatment with 2 mg of oral estradiol valerate in combination with 250 micrograms of levonorgestrel for the last ten days (Cyclo Progynova)
Number of subjects: 40
Study 8934257 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with 2 mg estradiol valerate orally in combination with a 20 micrograms per 24 hour levonorgestrel releasing intrauterine device
Number of subjects: 40
Study 8934257 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 40
Study 8320744 — intervention group
Group type: EXPERIMENTAL
Intervention: DDATHF 3.0 mg/m2 per week
Number of subjects: 33
Study 8320744 — intervention group
Group type: EXPERIMENTAL
Intervention: DDATHF 4.5 mg/m2 per week
Number of subjects: 33
Study 8320744 — intervention group
Group type: EXPERIMENTAL
Intervention: DDATHF 6.0 mg/m2 per week
Number of subjects: 33
Study 8320744 — intervention group
Group type: EXPERIMENTAL
Intervention: DDATHF
Number of subjects: 33
Study 2883003 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Epanolol-Visacor (ISA)
Number of subjects: 15
Study 2883003 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Metoprolol (without ISA)
Number of subjects: 15
Study 2883003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30281035 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0
Study 30281035 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 0
Study 27363578 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needling therapy (GV14 and acupuncture at EX-HN3, ST2, LI20, EX-HN8, GV23, LU7, LU5, LI4) three times a week for 4 weeks
Number of subjects: 98
Study 27363578 — intervention group
Group type: COMPARATOR
Intervention: Oral loratadine 10 mg/day for 4 weeks
Number of subjects: 98
Study 27363578 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needling therapy
Number of subjects: 98
Study 27363578 — intervention group
Group type: COMPARATOR
Intervention: Oral loratadine
Number of subjects: 98
Study 25711326 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline genotypic resistance testing
Number of subjects: 1946
Study 23643139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy
Number of subjects: 329
Study 23643139 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticogastrostomy
Number of subjects: 329
Study 20054841 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval (SR)
Number of subjects: 85
Study 20054841 — intervention group
Group type: EXPERIMENTAL
Intervention: Montessori-based activities
Number of subjects: 85
Study 20054841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 18511016 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral estradiol (oE(2))
Number of subjects: 50
Study 18511016 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg transdermal estradiol (tE(2))
Number of subjects: 50
Study 18511016 — intervention group
Group type: COMPARATOR
Intervention: Healthy premenopausal women
Number of subjects: 50
Study 18511016 — intervention group
Group type: COMPARATOR
Intervention: Normal postmenopausal women
Number of subjects: 50
Study 16819583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl infusion
Number of subjects: 40
Study 16819583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 40
Study 16819583 — intervention group
Group type: EXPERIMENTAL
Intervention: Response Entropy (RE)
Number of subjects: 40
Study 16819583 — intervention group
Group type: EXPERIMENTAL
Intervention: Response Entropy activation
Number of subjects: 40
Study 16819583 — intervention group
Group type: COMPARATOR
Intervention: BIS
Number of subjects: 40
Study 12767369 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha monotherapy
Number of subjects: 3065
Study 12767369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of surgery and immunotherapy
Number of subjects: 3065
Study 12767369 — intervention group
Group type: COMPARATOR
Intervention: Combination of IFN‐alpha and Il‐2
Number of subjects: 3065
Study 12767369 — intervention group
Group type: COMPARATOR
Intervention: Combination of IFN‐alpha, Il‐2 and 5‐fluorouracil (5‐FU)
Number of subjects: 3065
Study 10493320 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide (1000 microg twice daily)
Number of subjects: 60
Study 10493320 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1000 microg twice daily)
Number of subjects: 60
Study 10493320 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (1000 microg twice daily)
Number of subjects: 60
Study 10493320 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone (1000 microg twice daily)
Number of subjects: 60
Study 10493320 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (1000 microg twice daily)
Number of subjects: 60
Study 10493320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8087114 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation with positive end-expiratory pressure (CPPV)
Number of subjects: 8
Study 8087114 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled inverse ratio ventilation (PCIRV)
Number of subjects: 8
Study 2681551 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-shift cancer screening model
Number of subjects: 0
Study 2681551 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from a completed breast cancer screening RCT
Number of subjects: 0
Study 972558 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug profile provided to half of the study population for a full year.
Number of subjects: 1632
Study 972558 — intervention group
Group type: COMPARATOR
Intervention: No drug profile provided (control group).
Number of subjects: 1632
Study 31927220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (self-reported at baseline)
Number of subjects: 53
Study 30588705 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS intervention
Number of subjects: 20
Study 30588705 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 20
Study 28988170 — intervention group
Group type: EXPERIMENTAL
Intervention: HuCare Quality Improvement Strategy (HQIS)
Number of subjects: 720
Study 28988170 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 720
Study 26475731 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-domain optical coherence tomography (FD-OCT) assessment of morphometric stent parameters
Number of subjects: 10
Study 26475731 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative evaluation of strut coverage using FD-OCT
Number of subjects: 10
Study 23980354 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at acupoints combined general anesthesia (Group A)
Number of subjects: 90
Study 23980354 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture at non-acupoints combined general anesthesia (Group B)
Number of subjects: 90
Study 23980354 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Group C)
Number of subjects: 90
Study 21464262 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) for 20 minutes
Number of subjects: 25
Study 21464262 — intervention group
Group type: COMPARATOR
Intervention: Control group (quiet relaxation for 20 minutes)
Number of subjects: 25
Study 19095726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8901
Study 16923410 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of atrial high-rate episodes (AHRE) with pacemaker telemetry
Number of subjects: 400
Study 16923410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive atrial pacing
Number of subjects: 400
Study 16923410 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive testing capabilities of the pacemaker
Number of subjects: 400
Study 15144494 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalizing knowledge based on goals and topics (younger children)
Number of subjects: 256
Study 15144494 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering based on principles related to disciplines (older children)
Number of subjects: 256
Study 10996348 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo E4/4 (n=36)
Number of subjects: 1062
Study 10996348 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo E3/4 (n=209)
Number of subjects: 1062
Study 10996348 — intervention group
Group type: COMPARATOR
Intervention: Apo E3/3 (n=412)
Number of subjects: 1062
Study 10996348 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo E2/3 (n=66)
Number of subjects: 1062
Study 10996348 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo E4(+) (apo E3/4 and 4/4 combined)
Number of subjects: 1062
Study 9024260 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH infusion (1 microgram/kg bolus at 0900 h, then 1 microgram/kg/h for 21 h)
Number of subjects: 26
Study 9024260 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 infusion (1 microgram/kg bolus at 0900 h, then 1 microgram/kg/h for 21 h)
Number of subjects: 26
Study 9024260 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH plus GHRP-2 infusion
Number of subjects: 26
Study 9024260 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 26
Study 7898866 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-treatment group (5-FU injections started 2.4 +/- 0.6 days postoperatively)
Number of subjects: 28
Study 7898866 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment group (5-FU injections started 12.6 +/- 5.4 days postoperatively)
Number of subjects: 28
Study 7898866 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-treatment group
Number of subjects: 28
Study 7898866 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment group
Number of subjects: 28
Study 7898866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 3310297 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cytoxan, methotrexate, and 5-fluorouracil) for 1 year
Number of subjects: 311
Study 3310297 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF with tamoxifen for 1 year
Number of subjects: 311
Study 3310297 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF with or without bacillus Calmette-Guérin (BCG) for 1 year
Number of subjects: 311
Study 3310297 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with first local-regional recurrence
Number of subjects: 311
Study 3310297 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with any recurrence
Number of subjects: 311
Study 31844922 — intervention group
Group type: EXPERIMENTAL
Intervention: EPVL 3 days after RIRS
Number of subjects: 176
Study 31844922 — intervention group
Group type: EXPERIMENTAL
Intervention: EPVL 7 days after RIRS
Number of subjects: 176
Study 31844922 — intervention group
Group type: EXPERIMENTAL
Intervention: EPVL 14 days after RIRS
Number of subjects: 176
Study 31844922 — intervention group
Group type: COMPARATOR
Intervention: No EPVL after RIRS (Control Group)
Number of subjects: 176
Study 30064491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg then 40 mg 2 weeks later)
Number of subjects: 8
Study 30064491 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study 28854937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention a + b (workshop and intensive training)
Number of subjects: 9
Study 28854937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention a + b + c (workshop, intensive training, and action learning sets)
Number of subjects: 9
Study 28854937 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study 25952495 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-taking consistency
Number of subjects: 190
Study 24030939 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000-3000 IU/d)
Number of subjects: 26
Study 24030939 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 26
Study 24030939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21406000 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz appliances
Number of subjects: 60
Study 21406000 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 19014494 — intervention group
Group type: EXPERIMENTAL
Intervention: XM02 (5 microg/kg/day for at least 5 days and a maximum of 14 days)
Number of subjects: 348
Study 19014494 — intervention group
Group type: EXPERIMENTAL
Intervention: Neupogen (5 microg/kg/day for at least 5 days and a maximum of 14 days)
Number of subjects: 348
Study 19014494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 17147795 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortified instant noodles
Number of subjects: 425
Study 17147795 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 425
Study 17147795 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 425
Study 17147795 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortification
Number of subjects: 425